Cargando…
Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
An elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which causes progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the treatment of glaucoma. Tafluprost, a novel prostaglandin analogue, was recently...
Autor principal: | Aihara, Makoto |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850830/ https://www.ncbi.nlm.nih.gov/pubmed/20390038 |
Ejemplares similares
-
Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Pozarowska, Dorota
Publicado: (2010) -
Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
por: Schultz, Clyde
Publicado: (2011) -
First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost
por: Law, Simon K
Publicado: (2007) -
Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
por: Liu, Yang, et al.
Publicado: (2013) -
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)